<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article26</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PARTNER_3" style="display:block; margin-bottom:10px;">PARTNER 3 Original</a></li>
<h2><strong>PARTNER 3</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "TAVR versus Surgery for Aortic Stenosis in Patients at Low Surgical Risk".The New England Journal of Medicine. 2019. 380:1695-1705.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
<br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
   6.1 Inclusion Criteria<br/>
   6.2 Exclusion Criteria<br/>
   6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
   8.1 Primary Outcome<br/>
   8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Is transcatheter aortic-valve replacement (TAVR) superior to surgical aortic-valve replacement in patients with severe aortic stenosis who are at low surgical risk?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Among patients with severe aortic stenosis at low risk for surgical complications, TAVR significantly reduced rates of death, stroke, or rehospitalization at 1 year compared to surgery.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Previous studies established TAVR as a beneficial alternative to surgery in higher-risk patients with severe aortic stenosis. This trial assessed TAVR versus surgery in lower-risk patients, finding lower rates of key outcomes like death, strokes, and rehospitalization for TAVR, favoring its use in a wider patient population.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the last update, guidelines did not include the results of this trial for recommending treatments in low-risk patients. <br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized, nonblinded trial<br/>
- N=1,000 patients with severe aortic stenosis at low surgical risk<br/>
- Intervention: Transfemoral TAVR (n=503)<br/>
- Comparator: Surgical aortic-valve replacement (n=497)<br/>
- Primary outcome: Composite of death from any cause, stroke, or rehospitalization at 1 year<br/>
- Follow-Up: 1 year<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Severe, symptomatic aortic stenosis and low surgical risk<br/>
- STS-PROM (Society of Thoracic Surgeons Predicted Risk of Mortality) score &lt;4%<br/>
<br/>
Exclusion Criteria<br/>
- Clinical frailty, bicuspid aortic valves, or anatomy increasing the risk for both TAVR and surgery complications<br/>
<br/>
Baseline Characteristics<br/>
- Mean age: 73 years<br/>
- Male: 69.3%<br/>
- STS-PROM: 1.9%<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Transfemoral placement of a balloon-expandable SAPIEN 3 valve (TAVR group)<br/>
- Surgical aortic-valve replacement with commercially available bioprosthetic valve (surgery group)<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- TAVR: 8.5% had composite events at 1 year<br/>
- Surgery: 15.1% had composite events at 1 year<br/>
- Absolute difference: -6.6 percentage points (P&lt;0.001 for noninferiority and superiority)<br/>
<br/>
Secondary Outcomes<br/>
- Lower rates of stroke at 30 days (P=0.02)<br/>
- Shorter duration of the index_gpt hospitalization (P&lt;0.001)<br/>
- Lower rates of new-onset atrial fibrillation (P&lt;0.001)<br/>
- More rapid improvements in functional status and quality of life measures with TAVR<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- The trial was funded by Edwards Lifesciences.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- For additional information on this trial, readers can refer to the full journal article in The New England Journal of Medicine or the trial registration at ClinicalTrials.gov (NCT02675114).
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
